An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other autoimmune diseases — has reached an early development milestone. The treatment candidate, CDR111, is being developed under a collaboration between CDR-Life and Boehringer Ingelheim. The milestone was achieved after proof-of-concept studies in cells and animal models, […]

The post MS therapy CDR111 advances after meeting preclinical milestone appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com